These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11782586)

  • 1. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.
    Galli M; Ridolfo AL; Adorni F; Gervasoni C; Ravasio L; Corsico L; Gianelli E; Piazza M; Vaccarezza M; d'Arminio Monforte A; Moroni M
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):21-31. PubMed ID: 11782586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.
    Domingo P; Sambeat MA; Pérez A; Ordoñez J; Rodriguez J; Vázquez G
    Antivir Ther; 2003 Jun; 8(3):223-31. PubMed ID: 12924539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
    Mallal SA; John M; Moore CB; James IR; McKinnon EJ
    AIDS; 2000 Jul; 14(10):1309-16. PubMed ID: 10930144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.
    Melvin AJ; Lennon S; Mohan KM; Purnell JQ
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1117-23. PubMed ID: 11522181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
    AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.
    Arpadi SM; Cuff PA; Horlick M; Wang J; Kotler DP
    J Acquir Immune Defic Syndr; 2001 May; 27(1):30-4. PubMed ID: 11404517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body habitus alterations in HIV-infected women treated with combined antiretroviral therapy.
    Ridolfo AL; Gervasoni C; Bini T; Galli M
    AIDS Patient Care STDS; 2000 Nov; 14(11):595-601. PubMed ID: 11155901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy.
    Mulligan K; Tai VW; Algren H; Abrams DI; Leiser RJ; Lo JC; Schambelan M
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):443-8. PubMed ID: 11391163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
    HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
    Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.
    Barbaro G; Di Lorenzo G; Cirelli A; Grisorio B; Lucchini A; Hazra C; Barbarini G
    Clin Ther; 2003 Sep; 25(9):2405-18. PubMed ID: 14604740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.